interval, only 7% of 2467 patients undergoing CABG had single-vessel disease. 6 The fraction of CABG procedures currently performed for single-vessel disease is not likely to exceed that in the CASS study and is probably substantially lower.
Although virtually all patients presently treated with PTCA are suitable candidates for CABG, not all patients undergoing coronary bypass grafting are candidates for PTCA. In the CASS Registry, approximately 20% to 25% of patients with single-vessel disease who had CABG met conventional criteria for PTCA (proximal, discrete, subtotal, noncalcified stenosis in patients with well preserved ventricular function). 5 Based on the assumption that 200,000 CABG procedures are performed annually, no more than 37,000 (18.5%) would involve patients with single-vessel disease and only 9250 (25% of 37,000) of the surgically treated patients would be candidates for PTCA. If 50,000 PTCAs are being performed annually (a conservative estimate) and if 75% involve patients with single-vessel disease, a minimum of 37,500 patients with single-vessel disease are undergoing PTCA annually. Thus PTCA is being implemented in many patients (at least 28,000 per year) not currently considered candidates for CABG who would otherwise be managed medically. This phenomenon is extant even though PTCA may not be demonstrably more effective than medical management for this group of patients. The trend seems particulary questionable for treatment of patients with stable angina, since many of them experience improvement in functional capacity and maintain their employment status with medical therapy.7
Results of PTCA. The NHLBI Registry for PTCA has accumulated data from over 3000 patients treated in 105 centers between September 1977 and September 1981. Complete follow-up data are available for 2272 patients from 65 of the centers.9 Angiographic success was defined as a reduction in diameter narrowing of at least 20%. It was achieved in 1397 patients (61%). Seventy-two percent of these successfully treated patients (or 44% of the original group) were improved CIRCULATION and required no further procedures 1 year after the procedure, 14% had repeat PTCA, 12% required CABG, 3% sustained a myocardial infarction, and 1.6% died. Among the initially successfully treated patients, 67% were asymptomatic after 1 year. Recently reported higher initial success rates (80% to 85%) may reflect improved techniques and favorable patient selection. Despite improvement in initial success rate, angiographically determined rates of recurrent stenosis 6 to 12 months after PTCA have not been reduced, remaining 30% to 35%. Consequently, increasing numbers of patients are undergoing repeat procedures. Preliminary studies indicate that the restenosis rate after repeat PTCA may be lower than that after initial PTCA. Approximately 5% to 10% of patients treated with PTCA require urgent or emergent CABG. Hospital mortality, perioperative myocardial infarction, and postoperative complication rates are substantially higher for patients requiring emergent operation after PTCA than for those who undergo elective operation, particularly in the presence of multivessel disease.'0-12
Relief of symptoms by PTCA has been satisfactory in most patients with single-vessel disease. However, neither the extent of relief nor improvement in functional capacity have been shown to exceed appreciably those in candidates for PTCA treated medically.7 1 Symptomatic improvement may be less marked among patients with multivessel disease after PTCA, since all of the occlusive lesions may not be suitable for dilation and "incomplete revascularization" results. Incomplete revascularization among CABG patients results in a higher incidence of persistent or recurrent angina and this is also true for patients who undergo PITCA. 13 Employment status is maintained in a high percentage of patients after successful PTCA. However, it is also maintained in an equally high percentage of patients who have unsuccessful PTCA followed by CABG.'4 Not surprisingly, patients return to work more quickly after PTCA than after CABG. Despite these and other uncertainties regarding the effectiveness of PTCA in comparison with medical therapy and CABG, it has an established role in the treatment of symptomatic patients with coronary artery disease.
Costs. Costs of PTCA have been compared generally with those of CABG rather than with the costs of medical treatment per se. Using data acquired from patients with single-vessel disease in the NHLBI PTCA Registry at 11 centers and assuming an 80% initial success rate and a follow-up interval of 6 to 12 months, Jang et al. ' However, several occult and additional costs associated with PICA were ignored, such as costs for standby of surgeons, anesthesiologists, and operating room facilities. In a survey of 276 cardiac surgeons and surgical groups in 39 states of whom 175 (63%) responded anonymously to a questionnaire,* I found that 163 are available on a standby basis to respond to complications of PTCA and that 99 (57%) among these submit a charge for being available that ranges from $100 to $1000. Forty-six percent charge between $250 and $750. Thirty-nine percent of the standby anesthesiologists submit a charge of $100 to $750. An operating room is made available on a standby basis at 76% of the centers polled with charges levied for its availability ranging from $100 to $1000. Assuming that 50% of all centers (a conservative estimate) submit charges ($500 for the surgeon, $300 for the anesthesiologist, and $500 for the operating room), at least $650 should be added to the cost of each PTCA performed in the United States.
The analysis of Jang et al.'5 failed to consider costs of repeat catheterization, repeat angioplasty, or subsequent bypass grafting. In the PTCA Registry, 26% of patients required either repeat PTCA or CABG within 1 year after initial angioplasty.9 All of these (and probably many others in the Registry as a whole) had at least one repeat catheterization. Jang and co-workers failed to recognize that the patients undergoing CABG to which the PTCA group was compared contained a significantly higher percentage of patients over age 65 (27% vs 9% in the angioplasty group). Costs of CABG in elderly patients exceed those in younger patients because the duration of hospitalization is longer.'6 Thus, the calculated average cost for CABG is too high for comparative purposes.
A recent report from the Mayo Clinic compared expenditures for PTCA and CABG in patients with single-vessel disease during a 3 year interval ending in December 1981. '7 One year after the procedures, the mean monetary outlay was modestly (15%) lower for the PTCA-treated group. Charges for standby of surgeons and anesthesiologists were not included. A major component of the expense of PTCA was associated with the treatment of recurrent stenosis evident in 33% of patients within 1 year. Fifteen of the 55 patients in whom PTCA was sucessful initially required repeat PTCA (n = 6) or CABG (n = 9) during this interval. Only two of the 89 surgically treated patients required reoperation within the first year. The PTCA patients *A list of geographic locations of the surgeons responding is avail-
had a greater number of subsequent hospitalizations and hospital days.
It seems clear that unless the initial failure and restenosis rates of PTCA can be reduced substantially, cost savings from the widespread application of PTCA may be more apparent than real. Studies with longer intervals for follow-up are urgently needed to define the durabiity of PTCA.
Unresolved issues. In my view, the data available at present are insufficient to justify the inference that PTICA is more effective than medical management for patients with stable, mild, or moderate angina, or that it is more effective than CABG for patients with severe or unstable angina. The potential benefit of lower morbidity associated with PTCA may be offset by the increased mortality and rates of infarction associated with emergent operation, the need for repeat catheterization and repeat angioplasty, and risks associated with subsequently required CABG. Furthermore, the available analyses of costs suffer from incompleteness and limited follow-up. They do not conclusively document cost-effectiveness of PTCA compared with CABG. Of most importance, the durability of PTCA is questionable. The goal of postponement for 3 to 5 years of the need for CABG or for repeat PTCA may not be realized for most patients.
When CABG was first developing, critics and skeptics argued that it was being applied indiscriminately and that randomized trials were needed to determine whether or not it had a bona fide role in the treatment of coronary artery disease. Modern CABG was performed initially in 1967. The first large-scale randomized trial comparing CABG with medical therapy was initiated by the Veterans Administration in 1972. The NHLBI-sponsored randomized trial comparing medical and surgical treatment of patients with unstable angina was initiated in 1972. The CASS was initiated in 1974. Numerous single-center, randomized trials have been performed as well. Coronary PTCA was first reported in 1977. Remarkably, in the past 8 years not one multicenter prospective randomized trial comparing PTCA with medical therapy or with CABG has been initiated. The techniques for PTCA are now sufficiently standardized to permit valid comparison with current medical therapy and CABG.
Because most patients who undergo CABG are not candidates for PTCA according to current criteria, and because increasing numbers of patients are undergoing PTCA, one cannot escape the conclusion that large numbers of patients are being added to the pool of those subjected to aggressive interventions rather than being benefited by assignment to a less expensive pro-cedure as implied by the lay press.'8 The cost of this subtle excursion is not inconsequential.
Under conditions when an invasive procedure is clearly indicated and in our current social and economic climate, the implicit assumption that angioplasty is less expensive than CABG can lead to inappropriate therapeutic decisions. As an example, overt reimbursement for PTCA under the prospective payment system (diagnostic related groups, DRGs) entails payment through an ICD-9 category of 36.0 (direct surgery on the coronary arteries) in most hospitals placing the procedure in the DRG No. 108 (cardiothoracic surgery with pump except coronary bypass and valves).'9 This categorization may make PTCA seem to be a "bargain" to hospitals. Hospital administrators may therefore exert undue pressure on cardiologists and internists to perform the less expensive procedure, regardless of its therapeutic merit in comparison with CABG.
PTCA is being applied increasingly to patients with multivessel disease and with more extensive singlevessel disease including totally occluded vessels. Data available are insufficient to justify this trend on a large scale. Prospective, randomized trials comparing PTCA with medical therapy and with CABG are needed to define objectively the utility of PTCA. Subgroups of patients suitable for randomization have been recently proposed by Mock et al.20 Significant differences in survival may not be found even among patients with multivessel disease because of the favorable natural history of the patterns of coronary artery disease in many patients deemed suitable for PTCA.
However, other end points such as the extent and duration of relief of symptoms and improvement in functional capacity, subsequent infarction rate, need for secondary procedures, and cumulative costs can and must be characterized.
